BioVascular
San Diego
About BioVascular
BioVascular is a clinical stage privately held biotechnology company developing “first in class“ products for platelet mediated cardiovascular diseases. BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $10.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2008)
- Website: biovascularinc.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/biovascular-3716542 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.